Alnylam advances hypercholesterolemia drug with Tekmira's drug-delivery tech; Jazz Pharma taps drug-delivery vet to head R&D;

> The University of Michigan's Mohamed El-Sayed, Sophia Merajver and Yasmin Yuksel Durmaz has been awarded a $180,000 grant from Susan G. Komen for the Cure to advance drug-delivery vehicles to transport growth-inhibiting drugs to breast cancer tumors. Release

> InSite Vision has tapped Quintiles to run a Phase III clinical trial of AzaSite Plus and DexaSite for treating blepharitis. The products are formulated with a drug-delivery platform called DuraSite. Item

> Alnylam ($ALNY) has started giving patients its RNAi therapy ALN-PCS, which uses drug-delivery technology from Tekmira, in a Phase I trial. The drug is in development for treating severe hypercholesterolemia. Announcement

> Oramed Pharmaceuticals, which develops technology that enables oral delivery of meds that are now available by injection, said its tech licensee Entera succeeded in a Phase I study of an oral osteoporosis drug. Report

> Jazz Pharmaceuticals ($JAZZ) said it has tapped Jeffrey Tobias to be its head of R&D and chief medical officer, and the former NeurogesX executive comes to the job with drug-delivery experience. Release

> Celatorr Pharmaceuticals said that it has been granted a U.S. patent for intellectual property that supports its lead drug against leukemia, CPX-351, which combines cytarabine and daunorubicin with a liposome formulation. Item